Logo image of TARS

TARSUS PHARMACEUTICALS INC (TARS) Stock Overview

NASDAQ:TARS - US87650L1035 - Common Stock

57.2 USD
-0.05 (-0.09%)
Last: 8/25/2025, 12:20:52 PM

TARS Key Statistics, Chart & Performance

Key Statistics
52 Week High57.6
52 Week Low25.53
Market Cap2.41B
Shares42.21M
Float39.21M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.33
PEN/A
Fwd PE33.84
Earnings (Next)11-11 2025-11-11/amc
IPO10-16 2020-10-16
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


TARS short term performance overview.The bars show the price performance of TARS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

TARS long term performance overview.The bars show the price performance of TARS in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200 250

The current stock price of TARS is 57.2 USD. In the past month the price increased by 37.95%. In the past year, price increased by 124.25%.

TARSUS PHARMACEUTICALS INC / TARS Daily stock chart

TARS Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 43.19 660.17B
JNJ JOHNSON & JOHNSON 17.87 430.35B
NVO NOVO-NORDISK A/S-SPONS ADR 14.52 250.28B
AZN ASTRAZENECA PLC-SPONS ADR 17.97 247.43B
NVS NOVARTIS AG-SPONSORED ADR 14.19 243.07B
MRK MERCK & CO. INC. 11.06 212.71B
PFE PFIZER INC 7.46 143.70B
SNY SANOFI-ADR 11.42 122.81B
BMY BRISTOL-MYERS SQUIBB CO 6.99 95.80B
GSK GSK PLC-SPON ADR 8.82 79.87B
ZTS ZOETIS INC 24.98 68.85B
TAK TAKEDA PHARMACEUTIC-SP ADR 52.4 47.99B

About TARS

Company Profile

TARS logo image Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 323 full-time employees. The company went IPO on 2020-10-16. The firm is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The firm is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

Company Info

TARSUS PHARMACEUTICALS INC

15440 Laguna Canyon Road

Irvine CALIFORNIA 92618 US

CEO: Bobak Azamian

Employees: 323

TARS Company Website

TARS Investor Relations

Phone: 19494099820

TARSUS PHARMACEUTICALS INC / TARS FAQ

What is the stock price of TARSUS PHARMACEUTICALS INC today?

The current stock price of TARS is 57.2 USD. The price decreased by -0.09% in the last trading session.


What is the ticker symbol for TARSUS PHARMACEUTICALS INC stock?

The exchange symbol of TARSUS PHARMACEUTICALS INC is TARS and it is listed on the Nasdaq exchange.


On which exchange is TARS stock listed?

TARS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TARSUS PHARMACEUTICALS INC stock?

14 analysts have analysed TARS and the average price target is 75.19 USD. This implies a price increase of 31.45% is expected in the next year compared to the current price of 57.2. Check the TARSUS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TARSUS PHARMACEUTICALS INC worth?

TARSUS PHARMACEUTICALS INC (TARS) has a market capitalization of 2.41B USD. This makes TARS a Mid Cap stock.


How many employees does TARSUS PHARMACEUTICALS INC have?

TARSUS PHARMACEUTICALS INC (TARS) currently has 323 employees.


What are the support and resistance levels for TARSUS PHARMACEUTICALS INC (TARS) stock?

TARSUS PHARMACEUTICALS INC (TARS) has a support level at 41.3. Check the full technical report for a detailed analysis of TARS support and resistance levels.


Is TARSUS PHARMACEUTICALS INC (TARS) expected to grow?

The Revenue of TARSUS PHARMACEUTICALS INC (TARS) is expected to grow by 34040.4% in the next year. Check the estimates tab for more information on the TARS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy TARSUS PHARMACEUTICALS INC (TARS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TARSUS PHARMACEUTICALS INC (TARS) stock pay dividends?

TARS does not pay a dividend.


When does TARSUS PHARMACEUTICALS INC (TARS) report earnings?

TARSUS PHARMACEUTICALS INC (TARS) will report earnings on 2025-11-11, after the market close.


What is the Price/Earnings (PE) ratio of TARSUS PHARMACEUTICALS INC (TARS)?

TARSUS PHARMACEUTICALS INC (TARS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.33).


What is the Short Interest ratio of TARSUS PHARMACEUTICALS INC (TARS) stock?

The outstanding short interest for TARSUS PHARMACEUTICALS INC (TARS) is 20.75% of its float. Check the ownership tab for more information on the TARS short interest.


TARS Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to TARS. When comparing the yearly performance of all stocks, TARS is one of the better performing stocks in the market, outperforming 95.71% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TARS Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to TARS. While TARS seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TARS Financial Highlights

Over the last trailing twelve months TARS reported a non-GAAP Earnings per Share(EPS) of -2.33. The EPS increased by 47.99% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -18.58%
ROE -27.66%
Debt/Equity 0.22
Chartmill High Growth Momentum
EPS Q2Q%45.45%
Sales Q2Q%151.54%
EPS 1Y (TTM)47.99%
Revenue 1Y (TTM)254.46%

TARS Forecast & Estimates

14 analysts have analysed TARS and the average price target is 75.19 USD. This implies a price increase of 31.45% is expected in the next year compared to the current price of 57.2.

For the next year, analysts expect an EPS growth of 54.78% and a revenue growth 34040.4% for TARS


Analysts
Analysts87.14
Price Target75.19 (31.45%)
EPS Next Y54.78%
Revenue Next Year34040.4%

TARS Ownership

Ownership
Inst Owners103.25%
Ins Owners3.35%
Short Float %20.75%
Short Ratio12.58